Guanidine

Summary

Guanidine (CHEMBL821) is an approved small molecule; indicated across 2 conditions including neuroendocrine neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Chemistry: 59.07 Da · CH5N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL821
Name	Guanidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3520
ChEBI	CHEBI:42820
Molecular formula	CH5N3
Molecular weight	59.07
InChIKey	ZRALSGWEFCBTJO-UHFFFAOYSA-N

SMILES: C(=N)(N)N

IUPAC name: guanidine

ChEBI definition: An aminocarboxamidine, the parent compound of the guanidines.

Also known as: Guanidine, guanidinium, GUANIDINE CARBONATE, guanidine, GUANIDINE, GUANIDINE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1200728, CHEMBL3187576

Patent coverage: 103,268 distinct patent families (304,928 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuroendocrine neoplasm	3	MONDO:0019496	EFO:1001901

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).